J van der Weide - JoVE Visualize

Showing results (1-10 of 23) with videos related to

Pageof 3

Sort By:

Clinical Chemistry|May 20, 1998

Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplicationL S Steijns, J Van Der Weide

Annals of Clinical Biochemistry|December 10, 1999

Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacologyJ van der Weide, L S Steijns

Therapeutic Drug Monitoring|August 1, 1993

Evaluation of the cloned enzyme donor immunoassay for measurement of phenytoin and phenobarbital in serumJ van der Weide, H J Luiting, A H Veefkind

The Pharmacogenomics Journal|June 10, 2010

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patientsA de Vos, J van der Weide, H M Loovers

Neuroscience Letters|December 29, 1987

Autoradiographic localization of dopamine D2 receptors in the rat brain using the new agonist [3H]N-0437J van der Weide, M Camps, A S Horn, et al.

Nederlands Tijdschrift Voor Geneeskunde|October 13, 1990

[A family with hereditary spherocytosis discovered after an infection with human parvovirus B19]J van der Weide, H J Dijkhuis, C M Kremer, et al.

Clinica Chimica Acta; International Journal of Clinical Chemistry|April 30, 1996

Evaluation of nonisotopic binding assays for measuring vitamin B12 and folate in serumL S Steijns, J K Braams-Wiatrowska, H J Luiting, et al.

Pharmacogenetics|July 4, 2001

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirementJ van der Weide, L S Steijns, M J van Weelden, et al.

European Journal of Pharmacology|November 3, 1987

The effects of kainic acid and 6-hydroxydopamine lesions, metal ions and GTP on in vitro binding of the D-2 dopamine agonist, [3H]N-0437, to striatal membranesJ Van der Weide, J B De Vries, P G Tepper, et al.

Nederlands Tijdschrift Voor Geneeskunde|March 10, 2001

[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics]J van der Weide, L S Steijns, M J van Weelden, et al.

Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:

Pageof 3

Clinical Chemistry|May 20, 1998

Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplicationL S Steijns, J Van Der Weide

Annals of Clinical Biochemistry|December 10, 1999

Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacologyJ van der Weide, L S Steijns

Therapeutic Drug Monitoring|August 1, 1993

Evaluation of the cloned enzyme donor immunoassay for measurement of phenytoin and phenobarbital in serumJ van der Weide, H J Luiting, A H Veefkind

The Pharmacogenomics Journal|June 10, 2010

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patientsA de Vos, J van der Weide, H M Loovers

Neuroscience Letters|December 29, 1987

Autoradiographic localization of dopamine D2 receptors in the rat brain using the new agonist [3H]N-0437J van der Weide, M Camps, A S Horn, et al.

Nederlands Tijdschrift Voor Geneeskunde|October 13, 1990

[A family with hereditary spherocytosis discovered after an infection with human parvovirus B19]J van der Weide, H J Dijkhuis, C M Kremer, et al.

Clinica Chimica Acta; International Journal of Clinical Chemistry|April 30, 1996

Evaluation of nonisotopic binding assays for measuring vitamin B12 and folate in serumL S Steijns, J K Braams-Wiatrowska, H J Luiting, et al.

Pharmacogenetics|July 4, 2001

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirementJ van der Weide, L S Steijns, M J van Weelden, et al.

European Journal of Pharmacology|November 3, 1987

The effects of kainic acid and 6-hydroxydopamine lesions, metal ions and GTP on in vitro binding of the D-2 dopamine agonist, [3H]N-0437, to striatal membranesJ Van der Weide, J B De Vries, P G Tepper, et al.

Nederlands Tijdschrift Voor Geneeskunde|March 10, 2001

[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics]J van der Weide, L S Steijns, M J van Weelden, et al.

Pageof 3